Some clinical data have reported additiveor synergistic activity of IFN with rituximab in treatment of lymphomas [45–47].While many studies are centered the CD20 antibodies on tumor control, whether theantibodies have any effects on host innate immunity is unknown. This evidence concerns the gene IFNA1 and lymphoma.